Pharvaris NV
PHVS21.780USD
+0.820+3.91%
收盘 10/15, 16:00（美东）报价延迟15分钟
1.19B总市值
亏损市盈率 TTM
关于 Pharvaris NV 公司
Pharvaris BV 是一家位于瑞士的临床阶段公司。该公司的业务重点是生产口服缓激肽 B2 受体拮抗剂，并正在开发针对所有亚型遗传性血管性水肿 (HAE) 的注射疗法的新替代品。
Pharvaris NV简介
公司代码PHVS
公司名称Pharvaris NV
上市日期Feb 05, 2021
CEOMr. Berndt Modig, CPA
员工数量- -
证券类型Ordinary Share
年结日Feb 05
公司地址Emmy Noetherweg 2
城市LEIDEN
上市交易所NASDAQ Global Select Consolidated
国家Netherlands
邮编2333 BK
电话31712036410
网址https://pharvaris.com/
公司代码PHVS
上市日期Feb 05, 2021
CEOMr. Berndt Modig, CPA
Pharvaris NV公司高管
名称
名称/职务
职务
持股
持股变动
Dr. David P. Meeker ,M.D.
Dr. David P. Meeker ,M.D.
Non-Executive Director
Non-Executive Director
102.82K
-15.53%
Ms. Viviane Monges
Ms. Viviane Monges
Non-Executive Director
Non-Executive Director
54.91K
+73.10%
Ms. Anna Nijdam
Ms. Anna Nijdam
Head of Finance, Principal Accounting Officer
Head of Finance, Principal Accounting Officer
50.54K
+0.63%
Dr. Elisabeth Bjork, M.D., Ph.D.
Dr. Elisabeth Bjork, M.D., Ph.D.
Non-Executive Director
Non-Executive Director
50.53K
+128.70%
Mr. David W. Nassif, J.D.
Mr. David W. Nassif, J.D.
Chief Financial Officer
Chief Financial Officer
800.00
--
Dr. Jochen Knolle, Ph.D.
Dr. Jochen Knolle, Ph.D.
Co-Founder, Chief Operating Officer, Chief Scientific Officer
Co-Founder, Chief Operating Officer, Chief Scientific Officer
--
--
Dr. Peng Lu, M.D., Ph.D.
Dr. Peng Lu, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Anne Marie De Jonge Schuermans, Ph.D.
Dr. Anne Marie De Jonge Schuermans, Ph.D.
Non-Executive Director
Non-Executive Director
--
--
Mr. Berndt Modig, CPA
Mr. Berndt Modig, CPA
Chief Executive Officer, Co-Founder, Executive Director
Chief Executive Officer, Co-Founder, Executive Director
--
--
Dr. Morgan Conn, Ph.D.
Dr. Morgan Conn, Ph.D.
Chief Business Officer
Chief Business Officer
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. David P. Meeker ,M.D.
Dr. David P. Meeker ,M.D.
Non-Executive Director
Non-Executive Director
102.82K
-15.53%
Ms. Viviane Monges
Ms. Viviane Monges
Non-Executive Director
Non-Executive Director
54.91K
+73.10%
Ms. Anna Nijdam
Ms. Anna Nijdam
Head of Finance, Principal Accounting Officer
Head of Finance, Principal Accounting Officer
50.54K
+0.63%
Dr. Elisabeth Bjork, M.D., Ph.D.
Dr. Elisabeth Bjork, M.D., Ph.D.
Non-Executive Director
Non-Executive Director
50.53K
+128.70%
Mr. David W. Nassif, J.D.
Mr. David W. Nassif, J.D.
Chief Financial Officer
Chief Financial Officer
800.00
--
Dr. Jochen Knolle, Ph.D.
Dr. Jochen Knolle, Ph.D.
Co-Founder, Chief Operating Officer, Chief Scientific Officer
Co-Founder, Chief Operating Officer, Chief Scientific Officer
--
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 8月19日 周二
更新时间: 8月19日 周二
持股股东
股东类型
持股股东
持股股东
占比
General Atlantic LLC
11.76%
Fidelity Management & Research Company LLC
8.47%
Foresite Capital Management, LLC
6.89%
VenBio Partners LLC
6.70%
Viking Global Investors LP
5.70%
其他
60.49%
持股股东
持股股东
占比
General Atlantic LLC
11.76%
Fidelity Management & Research Company LLC
8.47%
Foresite Capital Management, LLC
6.89%
VenBio Partners LLC
6.70%
Viking Global Investors LP
5.70%
其他
60.49%
股东类型
持股股东
占比
Private Equity
25.72%
Investment Advisor
16.09%
Hedge Fund
14.25%
Venture Capital
13.60%
Investment Advisor/Hedge Fund
6.29%
Individual Investor
5.32%
Research Firm
0.08%
Bank and Trust
0.04%
Pension Fund
0.03%
其他
18.58%
机构持股
更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
115
48.75M
76.10%
-1.83M
2025Q2
125
52.21M
81.51%
-1.38M
2025Q1
125
53.89M
99.06%
+200.61K
2024Q4
123
53.45M
98.98%
+218.03K
2024Q3
114
53.86M
99.73%
+1.03M
2024Q2
83
52.08M
96.43%
-141.66K
2024Q1
76
49.63M
98.30%
-831.88K
2023Q4
69
47.76M
94.74%
+8.60M
2023Q3
54
36.05M
91.51%
-2.92M
2023Q2
53
35.78M
91.11%
+3.65M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
General Atlantic LLC
7.53M
11.76%
--
--
Jun 30, 2025
Fidelity Management & Research Company LLC
5.42M
8.47%
+27.02K
+0.50%
Jun 30, 2025
Foresite Capital Management, LLC
4.41M
6.89%
--
--
Jun 30, 2025
VenBio Partners LLC
4.29M
6.7%
--
--
Jun 30, 2025
Viking Global Investors LP
3.65M
5.7%
--
--
Jun 30, 2025
EQT Life Sciences
3.56M
5.55%
--
--
Apr 01, 2025
Bain Capital Life Sciences Investors, LLC
3.30M
5.16%
--
--
Jun 30, 2025
VR Adviser, LLC
2.05M
3.2%
-1.07M
-34.22%
Jun 30, 2025
Deerfield Management Company, L.P.
2.02M
3.15%
--
--
Jun 30, 2025
Commodore Capital LP
1.91M
2.98%
--
--
Jun 30, 2025
查看更多
持股ETF
更新时间: 10月6日 周一
更新时间: 10月6日 周一
机构名称
占比
Virtus LifeSci Biotech Clinical Trials ETF
0.98%
ALPS Medical Breakthroughs ETF
0.69%
iShares MSCI Netherlands ETF
0.21%
iShares MSCI Europe Small-Cap ETF
0.03%
SPDR S&P International Small Cap ETF
0.03%
Xtrackers MSCI Eurozone Hedged Eqty ETF
0.01%
iShares MSCI EAFE Small-Cap ETF
0.01%
Fidelity Nasdaq Composite Index ETF
0%
Avantis International Small Cap Equity ETF
0%
First Trust IPOX Europe Equity Opportunities ETF
0%
查看更多
Virtus LifeSci Biotech Clinical Trials ETF
占比0.98%
ALPS Medical Breakthroughs ETF
占比0.69%
iShares MSCI Netherlands ETF
占比0.21%
iShares MSCI Europe Small-Cap ETF
占比0.03%
SPDR S&P International Small Cap ETF
占比0.03%
Xtrackers MSCI Eurozone Hedged Eqty ETF
占比0.01%
iShares MSCI EAFE Small-Cap ETF
占比0.01%
Fidelity Nasdaq Composite Index ETF
占比0%
Avantis International Small Cap Equity ETF
占比0%
First Trust IPOX Europe Equity Opportunities ETF
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
